Please login to the form below

Not currently logged in
Email:
Password:

Intercytex

This page shows the latest Intercytex news and features for those working in and with pharma, biotech and healthcare.

UK regenerative medicine projects get £8.5m boost

An £8.5m package of grants will be shared by 14 projects in development by companies that include Cell Medica, Intercytex and Lonza Biologics. ... The projects will be led by: Altrika, Asymptote, Cell Medica, CellSeed Europe, Cellzome, ImmunoSolv,

Latest news

  • Take off

    Turnover was zero. Intercytex uses the body's own repair mechanisms to slow down ageing. ... Intercytex has a skin replacement product for burns, and is aiming for this to replace skin grafts.

  • Merger mania hits

    The company uses human cells for its skin and hair replacement products - a market that Intercytex believes is worth some $6bn in sales. ... Intercytex currently has a venous leg ulcer treatment in phase III trials and expects to release further

  • Bright backdrop

    On the new listings AIM front, where a wave of biotech and healthcare companies are thought to be putting the final touches to their plans for a flotation, Intercytex, a

  • Up and up?

    Meanwhile, Intercytex, a firm is working on a treatment for baldness, hopes to raise around £15m through a floatation on AIM.

  • Weathering the storm

    Intercytex seeks backing for serious wound product. Intercytex, the speciality pharmaceutical and biotech firm, posted a pre-tax loss of £11.6m on sales up 34 per cent to £111, 000. ... The company's lead product is a treatment for serious wounds and

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics